trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast', '$azn']
trastuzumab deruxtecan cuts risk of disease progression or death by 50% for patients with her2-low metastatic breast cancer #asco22 $azn 
Evidence-Based #Oncology. Bringing together perspectives of 20,000+ cancer care #providers, #payers, #policymakers, #patients, and researchers in #cancer care.